GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: DT-2216
                                 Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: DT2216 is a clinical stage PROTAC type protein degarder. It targets the BCL-XL protein (an anti-apoptotic protein that is overexpressed by some cancers) for degradation via the Von Hippel-Lindau (VHL) E3 ligase, and was developed for potential antitumour activity [2,4]. In vivo (in mice), The target protein binding moiety is based on the BCL-XL protein antagonist navitoclax (ABT-263) [2]. Since VHL is poorly expressed in platelets, DT2216 is significantly less toxic to platelets than parental navitoclax.
                                    
                                 | 
 | |||||||||||||||||||||||||||||||||||
For advanced searching click here to open chemical structure editor